Table 1 Demographic and clinical characteristics of the newly referred and long-term follow-up patients according to objective stratification levels
Newly referred patients | Long-term follow-up patients | |||||||
|---|---|---|---|---|---|---|---|---|
Level 1 (n = 9) | Level 2 (n = 125) | Level 3 (n = 111) | All (n = 245) | Level 1 (n = 18) | Level 2 (n = 236) | Level 3 (n = 165) | All (n = 419) | |
Age (years, range) | 55.3 (42–62) | 62.3 (23–89) | 65.8 (23–93) | 63.6 (23–93) | 55.3 (28–68) | 63.6 (19–89) | 68.6 (38–93) | 65.2 (19–93) |
Male sex – no. (%) | 3 (33.3) | 82 (65.6) | 71 (64.0) | 156 (63.7) | 9 (50) | 160 (67.8) | 113 (68.5) | 282 (67.3) |
BMI (kg/m2)a | 30.3 ± 8.2 | 30.5 ± 6.2 | 29.6 ± 5.3 | 30.1 ± 6.1 | 28.0 ± 5.3 | 30.1 ± 5.6 | 30.5 ± 5.9 | 30.2 ± 5.7 |
Diabetes duration - years | 3.9 ± 5.1 | 5.4 ± 5.8 | 7.9 ± 8.0 | 6.5 ± 7.0 | 6.2 ± 5.3 | 8.5 ± 6.0 | 11.5 ± 7.1 | 9.6 ± 6.6 |
SBP (mmHg) | 120.6 ± 7.0 | 140.6 ± 15.8 | 142.3 ± 24.4 | 140.7 ± 19.8 | 114.8 ± 9.1 | 134.0 ± 13.8 | 136.7 ± 17.4 | 134.3 ± 15.7 |
DBP (mmHg) | 70.9 ± 5.2 | 81.1 ± 9.5 | 80.0 ± 12.7 | 80.3 ± 11.1 | 72.3 ± 5.3 | 78.2 ± 8.7 | 76.8 ± 10.1 | 77.4 ± 9.2 |
HbA1c (%) (mmol/mol) | 6.3 ± 2.4 (45 ± 3) | 7.1 ± 3.1 (54 ± 10) | 8.5 ± 4.5 (69 ± 26) | 7.7 ± 4.1 (61 ± 21) | 6.1 ± 2.7 (43 ± 6) | 6.8 ± 3.1 (51 ± 10) | 7.6 ± 3.9 (60 ± 19) | 7.1 ± 3.5 (54 ± 15) |
TC (mmol/l) | 4.8 ± 0.8 | 4.4 ± 1.0 | 4.3 ± 1.2 | 4.3 ± 1.1 | 4.2 ± 1.4 | 4.0 ± 0.8 | 4.1 ± 1.1 | 4.0 ± 0.9 |
LDL-C (mmol/l) | 2.3 ± 0.7 | 2.2 ± 1.0 | 2.1 ± 0.9 | 2.2 ± 0.9 | 2.2 ± 1.1 | 1.8 ± 0.6 | 1.9 ± 1.0 | 1.8 ± 0.8 |
HDL-C(mmol/l) | 1.7 ± 0.4 | 1.3 ± 0.5 | 1.2 ± 0.4 | 1.3 ± 0.5 | 1.4 ± 0.4 | 1.3 ± 0.4 | 1.3 ± 0.4 | 1.3 ± 0.4 |
TG (mmol/l) | 1.9 ± 0.6 | 2.0 ± 1.2 | 2.3 ± 1.5 | 2.1 ± 1.3 | 1.2 ± 0.6 | 2.1 ± 1.2 | 2.2 ± 1.3 | 2.1 ± 1.2 |
Retinopathy – no. (%) | ||||||||
Any stage | 0 | 3 (2.4) | 6 (5.4) | 9 (3.7) | 0 | 20 (8.5) | 35 (21.2) | 55 (13.1) |
Macular oedema or | ||||||||
proliferative retinopathy | 0 | 0 | 3 (2.7) | 3 (1.2) | 0 | 0 | 4 (2.4) | 4 (1.0) |
Neuropathy – no. (%) | ||||||||
Peripheral neuropathy or insufficiency | 0 | 60 (48.0) | 58 (52.3) | 118 (48.2) | 0 | 128 (54.2) | 111 (67.3) | 139 (33.2) |
Previous or existing ulcer or Charcot foot | 0 | 0 | 8 (7.2) | 8 (3.3) | 0 | 0 | 13 (7.9) | 13 (3.1) |
Nephropathy – no. (%) | 0 | 0 | 36 (32.4) | 36 (14.7) | 0 | 0 | 89 (53.9) | 89 (21.2) |
Former MACE – no. (%) | 0 | 25 (20.0) | 34 (30.6) | 59 (24.1) | 0 | 45 (19.1) | 51 (30.9) | 96 (22.9) |
>1 MACE, symptomatic CVD or NYHA II-IV – no. (%) | 0 | 0 | 26 (23.4) | 26 (10.6) | 0 | 0 | 56 (33.9) | 56 (13.4) |